Comparative Pharmacology
Head-to-head clinical analysis: STELARA versus ZYNYZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: STELARA versus ZYNYZ.
STELARA vs ZYNYZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ustekinumab is a human IgG1κ monoclonal antibody that binds with high affinity and specificity to the p40 protein subunit of human interleukin (IL)-12 and IL-23, thereby blocking IL-12 and IL-23 mediated cell signaling and cytokine cascades.
ZYNYZ (futibatinib) is an irreversible, covalent inhibitor of fibroblast growth factor receptor (FGFR) 1-4. It binds to the ATP-binding pocket of FGFR and covalently modifies cysteine residue, leading to inhibition of FGFR phosphorylation and downstream signaling, thereby reducing tumor cell proliferation and angiogenesis.
Plaque psoriasis/Psoriatic arthritis: 45 mg subcutaneously (SC) for patients ≤100 kg or 90 mg SC for patients >100 kg at Weeks 0 and 4, then every 12 weeks. Crohn’s disease/Ulcerative colitis: Weight-based single intravenous induction dose (~6 mg/kg) at Week 0, followed by 90 mg SC at Week 8 and every 8 weeks thereafter.
Adults: 600 mg orally twice daily with or without food.
None Documented
None Documented
Terminal elimination half-life of approximately 3 weeks (range 15–32 days) in patients with psoriasis; supports subcutaneous dosing every 12 weeks.
Terminal elimination half-life is approximately 18-24 hours in patients with normal renal function. This supports once-daily or twice-daily dosing. Half-life is prolonged in renal impairment (up to >40 hours in severe impairment), requiring dose adjustment.
Primarily degraded into small peptides and individual amino acids; no significant renal or biliary excretion of intact antibody. Fecal excretion of degradation products is negligible.
Primarily renal excretion as unchanged drug (approximately 70-80% of the dose) via glomerular filtration and active tubular secretion. Biliary/fecal elimination accounts for <5% of the dose.
Category C
Category C
Interleukin Inhibitor
Interleukin Inhibitor